Guido Davidzon, MD
Clinical Assistant Professor
Boston University Chobanian & Avedisian School of Medicine

MD, Universidad Maimónides
MS, Massachusetts Institute of Technology

Dr. Guido A. Davidzon is a physician-scientist board certified in Nuclear Medicine. He graduated with honors from medical school in Argentina and completed an internship at Yale University New-Haven Hospital in Connecticut. He did his residency and was chief resident at Stanford Health Care. He completed a research fellowship in mitochondrial diseases at Columbia University in New York and, a U.S. National Library of Medicine Award supported, Biomedical Informatics fellowship at Massachusetts General Hospital in conjunction with a Science Masters at MIT.

Dr. Davidzon is Clinical Assistant Professor in the Department of Radiology at Stanford University and Chobanian and Avedisian School of Medicine. His clinical specialties include early diagnostic imaging of cancer, coronary artery disease, and dementias using molecular probes as well as the treatment of cancer for which he employs targeted radiopharmaceutical therapy.

Dr. Davidzon investigates the use of machine learning in medical imaging to improve clinical outcomes, he is involved in the professional Society of Nuclear Medicine and Molecular Imaging. He serves as a peer reviewer for multiple medical journals. Dr. Davidzon is a native of Buenos Aires, Argentina and has lived in the U.S. for over a decade. He travels to Argentina frequently, with his wife and three sons.

Kaiser Permanente Santa Clara Medical Center

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Song H, Ferri V, Duan H, Aparici CM, Davidzon G, Franc BL, Moradi F, Nguyen J, Shah J, Iagaru A. SPECT at the speed of PET: a feasibility study of CZT-based whole-body SPECT/CT in the post 177Lu-DOTATATE and 177Lu-PSMA617 setting. Eur J Nucl Med Mol Imaging. 2023 Mar 04. PMID: 36869177
  2. Duan H, Ghanouni P, Daniel B, Rosenberg J, Thong A, Kunder C, Mari Aparici C, Davidzon GA, Moradi F, Sonn GA, Iagaru A. A Pilot Study of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer. J Nucl Med. 2022 Nov 17. PMID: 36396456
  3. Wilson EN, Young CB, Ramos Benitez J, Swarovski MS, Feinstein I, Vandijck M, Le Guen Y, Kasireddy NM, Shahid M, Corso NK, Wang Q, Kennedy G, Trelle AN, Lind B, Channappa D, Belnap M, Ramirez V, Skylar-Scott I, Younes K, Yutsis MV, Le Bastard N, Quinn JF, van Dyck CH, Nairn A, Fredericks CA, Tian L, Kerchner GA, Montine TJ, Sha SJ, Davidzon G, Henderson VW, Longo FM, Greicius MD, Wagner AD, Wyss-Coray T, Poston KL, Mormino EC, Andreasson KI. Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer's disease. Alzheimers Res Ther. 2022 Nov 12; 14(1):172. PMID: 36371232; PMCID: PMC9652927; DOI: 10.1186/s13195-022-01116-2;
  4. Duan H, Ghanouni P, Daniel B, Rosenberg J, Davidzon GA, Mari Aparici C, Kunder C, Sonn G, Iagaru A. A Pilot Study of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High Intensity Focused Ultrasound (HIFU) Therapy. J Nucl Med. 2022 Nov 03. PMID: 36328488
  5. Duan H, Ferri V, Fisher GA, Shaheen S, Davidzon GA, Iagaru A, Mari Aparici C. Evaluation of Liver and Renal Toxicity in Peptide Receptor Radionuclide Therapy for Somatostatin Receptor Expressing Tumors: A 2-Year Follow-Up. Oncologist. 2022 Jun 08; 27(6):447-452. PMID: 35641196; PMCID: PMC9177120; DOI: 10.1093/oncolo/oyab072;
  6. Duan H, Baratto L, Fan RE, Soerensen SJC, Liang T, Chung BI, Thong AEC, Gill H, Kunder C, Stoyanova T, Rusu M, Loening AM, Ghanouni P, Davidzon GA, Moradi F, Sonn GA, Iagaru A. Correlation of 68Ga-RM2 PET with Postsurgery Histopathology Findings in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer. J Nucl Med. 2022 Dec; 63(12):1829-1835. PMID: 35552245
  7. Moradi F, Duan H, Song H, Davidzon GA, Chung BI, Thong AEC, Loening AM, Ghanouni P, Sonn G, Iagaru A. 68Ga-PSMA-11 PET/MRI in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Adenocarcinoma: PET Findings Correlate with Outcomes After Definitive Treatment. J Nucl Med. 2022 Dec; 63(12):1822-1828. PMID: 35512996
  8. Napolioni V, Fredericks CA, Kim Y, Channappa D, Khan RR, Kim LH, Zafar F, Couthouis J, Davidzon GA, Mormino EC, Gitler AD, Montine TJ, Schüle B, Greicius MD. Phenotypic Heterogeneity among GBA p.R202X Carriers in Lewy Body Spectrum Disorders. Biomedicines. 2022 Jan 12; 10(1). PMID: 35052839; PMCID: PMC8774039; DOI: 10.3390/biomedicines10010160;
  9. Hall JN, Mormino E, Ng A, Boumis A, Gaudioso JL, Davidzon GA, Sha SJ. Six Recurrent Amyloid-Related Imaging Abnormality Episodes in a Patient Treated With Aducanumab. JAMA Neurol. 2022 01 01; 79(1):87-89. PMID: 34747986; PMCID: PMC9677548; DOI: 10.1001/jamaneurol.2021.3933;
  10. Duan H, Baratto L, Hatami N, Liang T, Mari Aparici C, Davidzon GA, Iagaru A. 68Ga-PSMA11 PET/CT for biochemically recurrent prostate cancer: Influence of dual-time and PMT- vs SiPM-based detectors. Transl Oncol. 2022 Jan; 15(1):101293. PMID: 34823095; PMCID: PMC8626686; DOI: 10.1016/j.tranon.2021.101293;
Showing 10 of 65 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 65 publications over 18 distinct years, with a maximum of 12 publications in 2021


In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Nuclear Medicine
Molecular Imaging
Positron Emission Tomography
Targeted Radionuclide Therapy
Contact for Mentoring:

820 Harrison Ave
Boston MA 02118
Google Map

Davidzon's Networks
Click the "See All" links for more information and interactive visualizations
Similar People
Same Department